Biotechnology - Pharmaceutical, Antibiotics and Infectious diseases

Filter

Popular Filters

Soligenix and Intrexon collaborate on Melioidosis therapy development

01-05-2013

US clinical stage biopharma company Soligenix (OTCBB: SNGX) says it will jointly develop a treatment…

Antibiotics and Infectious diseasesBiotechnologyIntrexonLicensingPharmaceuticalResearchSoligenix

NeRRe Therapeutics created to develop NRAs from GSK; GlycoVaxyn deal with GSK

20-12-2012

NeRRe Therapeutics was launched in the UK yesterday to develop a portfolio of clinical and pre-clinical…

Antibiotics and Infectious diseasesBiotechnologyFinancialGlaxoSmithKlineGlycoVaxynLicensingNeRReTherapeuticsNeurologicalNovo NordiskPharmaceuticalResearchVaccines

GlaxoSmithKline amends accord with Isis Pharma; gets FDA panel backing for raxibacumab

06-11-2012

USA-based Isis Pharmaceuticals (Nasdaq: ISIS) says it has agreed to amend the clinical development plan…

Antibiotics and Infectious diseasesBiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsISIS-TTR.RXLicensingNorth AmericaPharmaceuticalRare diseasesraxibacumabRegulationResearch

UK's NICE launches new medicines advisory service

15-07-2012

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) last Friday launched…

Antibiotics and Infectious diseasesAstellas PharmaBiotechnologyDificlirEuropeGenericsPharmaceuticalRegulation

News briefs: TB drug developments at Jansen and AstraZeneca; NPS/Amgen deal amended

03-07-2012

US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Research & Development unit has submitted…

AmgenAntibiotics and Infectious diseasesAstraZenecabedaquilineBiotechnologyCellworkscinacalcetJanssenJohnson & JohnsonLicensingMetabolicsNPS PharmaceuticalsPharmaceuticalRegulationResearch

TaiGen Biotech out-licenses China rights for nemonoxacin, to Zhejiang Medicine

26-06-2012

Taiwan-based TaiGen Biotechnology and China's Zhejiang Medicine Company (SHA: 600216) have signed an…

Antibiotics and Infectious diseasesAsia-PacificBiotechnologyLicensingnemonoxacinPharmaceuticalTaiGen BiotecnologyZhejiang Medicine

Forest acquires rights to Nabriva antibacterial and option to buy firm

04-06-2012

US drugmaker Forest Laboratories (NYSE: FRX) says it has entered into an agreement with Austrian biotech…

Antibiotics and Infectious diseasesBC-3781BiotechnologyForest LaboratoriesLicensingMergers & AcquisitionsNabriva TherapeuticsPharmaceutical

Back to top